U.S. Markets open in 2 hrs 41 mins

Trovagene, Strand Life Sciences to commercialize urine-based HPV test

Trovagene and Strand Life Sciences Pvt Ltd., of Bangalore, India, completed their agreement to validate and commercialize Trovagene's proprietary urine-based Human Papillomavirus, or HPV, test for clinical diagnostic and carrier screening use. Trovagene's urine-based HPV test is designed to allow for completely non-invasive HPV carrier screening. Strand's initial target market is an estimated population of over 450M women between the ages 18 and 65 in India and South Asia.